journal
Journals European Neuropsychopharmacolo...

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology

https://read.qxmd.com/read/38579661/methods-for-neuroscience-drug-development-guidance-on-standardization-of-the-process-for-defining-clinical-outcome-strategies-in-clinical-trials
#1
JOURNAL ARTICLE
Silvia Zaragoza Domingo, Jordi Alonso, Montse Ferrer, Maria T Acosta, Larry Alphs, Peter Annas, Pavel Balabanov, Anna-Karin Berger, Kim I Bishop, Florence Butlen-Ducuing, Georg Dorffner, Chris Edgar, Manuel de Gracia Blanco, Brian Harel, John Harrison, William P Horan, Judith Jaeger, Jan Kottner, Amy Pinkham, Daniella Tinoco, Monika Vance, Christian Yavorsky
Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early clinical trials is key to maximizing the likelihood of identifying new treatments in psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore The Outcomes Research Group was formed to develop and promote good practices in outcome selection. This article describes the first published guidance on the standardization of the process for clinical outcomes in neuroscience...
April 3, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38547544/eli-robins-the-grandfather-of-dsm-iii
#2
JOURNAL ARTICLE
Brian Kirkpatrick, Emilio Fernandez-Egea
No abstract text is available yet for this article.
March 27, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38518409/how-do-lipids-fit-into-the-picture-of-severe-mental-health-disorders-a-missing-pathophysiologic-link-or-just-a-consequence-of-behavior-and-treatment
#3
JOURNAL ARTICLE
Eva C Schulte, Thomas G Schulze
No abstract text is available yet for this article.
March 21, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38508100/exploring-the-association-between-suicidal-thoughts-self-injury-and-glp-1-receptor-agonists-in-weight-loss-treatments-insights-from-pharmacovigilance-measures-and-unmasking-analysis
#4
JOURNAL ARTICLE
A Guirguis, S Chiappini, G D Papanti P, R Vickers-Smith, D Harris, J M Corkery, D Arillotta, G Floresta, G Martinotti, F Schifano
INTRODUCTION: The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA). AIM: The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators. METHODS: Descriptive and pharmacovigilance disproportionality analyses was performed. RESULTS: A total of 209,354 ADRs were reported, including 59,300 serious cases...
March 19, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38503084/mindfulness-based-cognitive-therapy-neurobiology-in-treatment-resistant-obsessive-compulsive-disorder-a-domain-related-resting-state-networks-approach
#5
JOURNAL ARTICLE
Víctor De la Peña-Arteaga, Marta Cano, Daniel Porta-Casteràs, Muriel Vicent-Gil, Neus Miquel-Giner, Ignacio Martínez-Zalacaín, Lorea Mar-Barrutia, Marina López-Solà, Jessica R Andrews-Hanna, Carles Soriano-Mas, Pino Alonso, Maria Serra-Blasco, Clara López-Solà, Narcís Cardoner
Mindfulness-based cognitive therapy (MBCT) stands out as a promising augmentation psychological therapy for patients with obsessive-compulsive disorder (OCD). To identify potential predictive and response biomarkers, this study examines the relationship between clinical domains and resting-state network connectivity in OCD patients undergoing a 3-month MBCT programme. Twelve OCD patients underwent two resting-state functional magnetic resonance imaging sessions at baseline and after the MBCT programme. We assessed four clinical domains: positive affect, negative affect, anxiety sensitivity, and rumination...
March 18, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38492550/trait-anxiety-is-associated-with-attentional-brain-networks
#6
JOURNAL ARTICLE
Víctor De la Peña-Arteaga, Pamela Chavarría-Elizondo, Asier Juaneda-Seguí, Ignacio Martínez-Zalacaín, Pedro Morgado, José Manuel Menchón, Maria Picó-Pérez, Miquel A Fullana, Carles Soriano-Mas
Trait anxiety is a well-established risk factor for anxiety and depressive disorders, yet its neural correlates are not clearly understood. In this study, we investigated the neural correlates of trait anxiety in a large sample (n = 179) of individuals who completed the trait and state versions of the State-Trait Anxiety Inventory and underwent resting-state functional magnetic resonance imaging. We used independent component analysis to characterize individual resting-state networks (RSNs), and multiple regression analyses to assess the relationship between trait anxiety and intrinsic connectivity...
March 15, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38492513/choosing-lithium-in-the-perinatal-period-lower-dose-in-the-first-trimester-of-pregnancy
#7
LETTER
Veerle Bergink
No abstract text is available yet for this article.
March 15, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38492329/identification-and-treatment-of-individuals-with-childhood-onset-and-early-onset-schizophrenia
#8
REVIEW
Christoph U Correll, Celso Arango, Birgitte Fagerlund, Silvana Galderisi, Martien J Kas, Stefan Leucht
Approximately 8 % of patients with schizophrenia are diagnosed before age 18, and 18 % experience their first symptoms before age 18. This narrative review explores the management of patients with early-onset schizophrenia (EOS) and childhood-onset schizophrenia (COS) from diagnosis to their transition to adult care settings. Early diagnosis of schizophrenia in children and adolescents is essential for improving outcomes, but delays are common due to overlapping of symptoms with developmental phenomena and other psychiatric conditions, including substance use, and lack of clinicians' awareness...
March 15, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490086/the-why-and-the-how-of-transdiagnostic-clinical-research-in-youth-psychiatry
#9
JOURNAL ARTICLE
Covadonga M Díaz-Caneja, Sinan Guloksuz
No abstract text is available yet for this article.
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490085/the-pros-and-cons-of-banning-electronic-cigarettes
#10
JOURNAL ARTICLE
Wim van den Brink, Jan van Amsterdam
No abstract text is available yet for this article.
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490084/parvalbumin-interneuron-deficits-in-schizophrenia
#11
REVIEW
Oscar Marín
Parvalbumin-expressing (PV+) interneurons represent one of the most abundant subclasses of cortical interneurons. Owing to their specific electrophysiological and synaptic properties, PV+ interneurons are essential for gating and pacing the activity of excitatory neurons. In particular, PV+ interneurons are critically involved in generating and maintaining cortical rhythms in the gamma frequency, which are essential for complex cognitive functions. Deficits in PV+ interneurons have been frequently reported in postmortem studies of schizophrenia patients, and alterations in gamma oscillations are a prominent electrophysiological feature of the disease...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490083/a-randomised-placebo-controlled-double-blind-crossover-trial-on-the-effect-of-a-20-1-cannabidiol-%C3%AE-9-tetrahydrocannabinol-medical-cannabis-product-on-neurocognition-attention-and-mood
#12
JOURNAL ARTICLE
Brooke Manning, Amie C Hayley, Sarah Catchlove, Con Stough, Luke A Downey
As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg Δ9-tetrahydrocannabinol (THC) on neurocognition, attention, and mood. A randomised, double-blind, placebo-controlled, within-subjects design assessed 31 healthy participants (16 female, 15 male), aged between 21 and 58 years, over a two-week experimental protocol...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490082/suicide-mortality-in-spain-during-the-covid-19-pandemic-longitudinal-analysis-of-sociodemographic-factors
#13
JOURNAL ARTICLE
Alejandro de la Torre-Luque, Ivan Perez-Diez, Andres Pemau, Gonzalo Martinez-Ales, Guilherme Borges, Victor Perez-Sola, Jose Luis Ayuso-Mateos
The COVID-19 pandemic has compromised public health response across the globe. Several countries reported increasing number of suicides during the pandemic. This study aimed to analyze the suicide mortality series in Spain (2000-2021), with a particular interest in depicting longitudinal trends during the COVID-19 pandemic. Moreover, it intended to identify sociodemographic groups with a higher increase in suicide victims during the pandemic. To do so, suicide cases from the National death index data were used...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490017/antidepressants-and-suicide-more-benefit-than-harm
#14
JOURNAL ARTICLE
Erkki Isometsä
No abstract text is available yet for this article.
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490016/efficacy-acceptability-and-side-effects-of-oral-versus-long-acting-injectables-antipsychotics-systematic-review-and-network-meta-analysis
#15
REVIEW
Dongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, Mengchang Qin, Hui Wu, Yikang Zhu, John M Davis, Josef Priller, Stefan Leucht
Long-acting injectable antipsychotics (LAIs) are primarily used for relapse prevention, but in some settings and situations, they may also be useful for acute treatment of schizophrenia. We conducted a systematic review and frequentist network meta-analysis of randomized-controlled trials (RCTs), focusing on adult patients in the acute phase of schizophrenia. Interventions were risperidone, paliperidone, aripiprazole, olanzapine, and placebo, administered either orally or as LAI. We synthesized data on overall symptoms, complemented by 17 other efficacy and tolerability outcomes...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38490015/settling-a-distracted-globe-an-overview-of-psychosocial-and-psychotherapeutic-treatment-of-attention-deficit-hyperactivity-disorder
#16
REVIEW
Xenia Gonda, Sara Balint, Janos Miklos Rethelyi, Peter Dome
While the currently prevailing theory of ADHD postulates a neurobiological background and core deficits of behavioural inhibition and executive functioning as the basis of ADHD symptoms, our current conceptualisation also acknowledges the essential contributory role of psychosocial, ecological, and cognitive factors. Considering the multifactorial background of ADHD, its treatment equally needs to be multifactorial involving, besides pharmacotherapy, skill development and psychotherapy as well, especially if we postulate the increasing contribution of social factors in the background of the increasing burden of ADHD...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38489853/assessing-risk-for-bipolar-disorder-comments-on-young-people-at-risk-for-developing-bipolar-disorder-two-year-findings-from-the-multicenter-prospective-naturalistic-early-bipolife-study-martini-et-al-2023
#17
LETTER
Mireia Solerdelcoll, Inmaculada Baeza, Gisela Sugranyes
No abstract text is available yet for this article.
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38401406/residual-effects-of-medications-for-sleep-disorders-on-driving-performance-a-systematic-review-and-network-meta-analysis-of-randomized-controlled-trials-nma-driving-and-hypnotics
#18
JOURNAL ARTICLE
Michele Fornaro, Claudio Caiazza, Flavia Rossano, Flavia Cilmi, Michele De Prisco, Eduard Vieta, Trevor Thompson, Marco Solmi, Andre Ferrer Carvalho, Felice Iasevoli, Andrea de Bartolomeis
Sleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized Mean Difference/SMD) and driving impairment rates on the first morning (co-primary outcomes) and endpoint...
February 23, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38368796/regional-differences-in-mortality-risk-and-in-attenuating-or-aggravating-factors-in-schizophrenia-a-systematic-review-and-meta-analysis
#19
REVIEW
Marco Solmi, Giovanni Croatto, Michele Fornaro, Lynne Kolton Schneider, S Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Merete Nordentoft, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Laurent Boyer, Michele De Prisco, Eduard Vieta, Christoph U Correll
People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality...
February 17, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38359657/does-valerian-work-for-insomnia-an-umbrella-review-of-the-evidence
#20
REVIEW
Valéria Valente, Daniela Machado, Susana Jorge, Christopher L Drake, Daniel Ruivo Marques
Valerian is one of the most used herbal agents (phytotherapeutics) to manage sleep disturbances, in particular, sleep-onset difficulties in young adults. However, the evidence based on primary studies and systematic reviews that supports its use in this domain is weak or inconclusive. In the current study, an umbrella review was performed on the efficacy of valerian for sleep disturbances with a focus on insomnia. As such, only systematic reviews (with or without meta-analysis) were considered for this study...
February 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
journal
journal
30810
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.